Chemoimmunotherapy with Cyclophosphamide, IL-2, and LAK Cells in Mice
Author Information
Author(s): A.M.M. Eggermont, P.H. Sugarbaker
Primary Institution: Surgery Branch, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Hypothesis
The study investigates the efficacy of combining low doses of cyclophosphamide with interleukin-2 and lymphokine activated killer cells in treating intraperitoneal tumors in mice.
Conclusion
The combination treatment significantly improved survival and tumor reduction in mice compared to single treatments.
Supporting Evidence
- Combination treatment led to a significant survival benefit.
- About 25% of the mice were cured even with increased tumor cell doses.
- Combination therapy was more effective than single treatment modalities.
Takeaway
Researchers found that using a mix of medicines helped mice with tumors live longer and have less cancer.
Methodology
Mice were treated with different doses of cyclophosphamide, IL-2, and LAK cells, and tumor growth was assessed using the peritoneal cancer index.
Limitations
The scoring system for tumor load was crude, which may have affected the statistical significance of the results.
Participant Demographics
C57BL/6 female mice, aged 9-12 weeks.
Statistical Information
P-Value
0.0002
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website